These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 16267739)

  • 21. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients.
    Molina JM; Ferchal F; Rancinan C; Raffi F; Rozenbaum W; Sereni D; Morlat P; Journot V; Decazes JM; Chêne G
    J Infect Dis; 2000 Aug; 182(2):599-602. PubMed ID: 10915095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recreational substance use and tolerance of efavirenz in HIV-1 infected patients.
    Faggian F; Lattuada E; Lanzafame M; Antolini D; Concia E; Vento S
    AIDS Care; 2005 Oct; 17(7):908-10. PubMed ID: 16120507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
    Molina JM; Journot V; Morand-Joubert L; Yéni P; Rozenbaum W; Rancinan C; Fournier S; Morlat P; Palmer P; Dupont B; Goujard C; Dellamonica P; Collin F; Poizot-Martin I; Chene G;
    J Infect Dis; 2005 Mar; 191(6):830-9. PubMed ID: 15717256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals.
    Poeta J; Linden R; Antunes MV; Real L; Menezes AM; Ribeiro JP; Sprinz E
    J Antimicrob Chemother; 2011 Nov; 66(11):2601-4. PubMed ID: 21890538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).
    Djabarouti S; Breilh D; Pellegrin I; Lavit M; Camou F; Caubet O; Fleury H; Saux MC; Pellegrin JL
    J Antimicrob Chemother; 2006 Nov; 58(5):1090-3. PubMed ID: 16921181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?
    Dahri K; Ensom MH
    Clin Pharmacokinet; 2007; 46(2):109-32. PubMed ID: 17253884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
    Waters L; Fisher M; Winston A; Higgs C; Hadley W; Garvey L; Mandalia S; Perry N; Nicola M; Nelson M
    AIDS; 2011 Jan; 25(1):65-71. PubMed ID: 21099666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines.
    von Hentig N; Koenigs C; Elanjikal S; Linde R; Dunsch D; Kreuz W; Funk MB
    Eur J Med Res; 2006 Sep; 11(9):377-80. PubMed ID: 17101460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
    Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA;
    N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.
    Gallien S; Journot V; Loriot MA; Sauvageon H; Morlat P; Reynes J; Reliquet V; Chêne G; Molina JM;
    HIV Med; 2017 Sep; 18(8):537-545. PubMed ID: 28145050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evidence-based therapeutic drug monitoring for efavirenz].
    Solas C; Gagnieu MC;
    Therapie; 2011; 66(3):197-205. PubMed ID: 21819803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.
    Clifford DB; Evans S; Yang Y; Acosta EP; Goodkin K; Tashima K; Simpson D; Dorfman D; Ribaudo H; Gulick RM
    Ann Intern Med; 2005 Nov; 143(10):714-21. PubMed ID: 16287792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.
    Pedrol E; Llibre JM; Tasias M; Currán A; Guardiola JM; Deig E; Guelar A; Martínez-Madrid O; Tikhomirova L; Ramírez R;
    HIV Med; 2015 Nov; 16(10):628-34. PubMed ID: 26238151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efavirenz intoxication due to slow hepatic metabolism.
    Hasse B; Günthard HF; Bleiber G; Krause M
    Clin Infect Dis; 2005 Feb; 40(3):e22-3. PubMed ID: 15668854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men.
    Reddy YS; Gotzkowsky SK; Eron JJ; Kim JY; Fiske WD; Fiscus SA; Petch L; Cohen MS; Kashuba AD
    J Infect Dis; 2002 Nov; 186(9):1339-43. PubMed ID: 12402205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study.
    van Luin M; Bannister WP; Mocroft A; Reiss P; Di Perri G; Peytavin G; Molto J; Karlson A; Castagna A; Beniowski M; Lundgren JD; Burger DM;
    Antivir Ther; 2009; 14(1):75-83. PubMed ID: 19320239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021.
    McKinney RE; Rodman J; Hu C; Britto P; Hughes M; Smith ME; Serchuck LK; Kraimer J; Ortiz AA; Flynn P; Yogev R; Spector S; Draper L; Tran P; Scites M; Dickover R; Weinberg A; Cunningham C; Abrams E; Blum MR; Chittick GE; Reynolds L; Rathore M;
    Pediatrics; 2007 Aug; 120(2):e416-23. PubMed ID: 17646352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash.
    Manosuthi W; Thongyen S; Chumpathat N; Muangchana K; Sungkanuparph S
    HIV Med; 2006 Sep; 7(6):378-82. PubMed ID: 16903982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.